| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-743 | |
| Phytochemical name or plant extracts | Protopheophorbide A | |
| PMID | 29978911 | |
| Literature evidence | Thus, the hepatocyte growth factor (HGF)/c-Met signaling axis has gained considerable attention as a valid molecular target for breast cancer therapy. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Chlorophyll derivative | |
| Source of phytochemicals or plant Extracts | Ziziphus lotus | |
| Geographical availability | Algeria, Burkina, Cyprus, Egypt, Greece, Gulf States, Lebanon-Syria, Libya, Mali, Mauritania, Morocco, Niger, Palestine, Sicilia, Spain, Tunisia, Turkey, Western Sahara | |
| Plant parts | Leaves | |
| Other cancers | Breast cancer | |
| Target gene or protein | E-cadherin, Vimentin, β-catenin, FAK, Brk, Rac, Src | |
| Gene or Protein evidence | Moreover, protopheophorbide A exhibited anti-migratory properties (IC50 = 2.2 μM) through impacting the expression levels of E-cadherin, vimentin, β-catenin, FAK, Brk, Rac, and Src proteins. | |
| Target pathways | RAF/MEK/ERK signaling pathways PI3K/PTEN/AKT signaling pathways | |
| IC50 | 6.5 μM against MDA-MB-231 | |
| Potency | Our results suggest that protopheophorbide A could be a novel c-Met inhibitory lead with promise to control c-Met/HGF-dependent breast malignancies. | |
| Cell line/ mice model | MDA-MB-231, MCF-7 | |
| Additional information | Importantly, treatment with protopheophorbide A significantly inhibited the MDA-MB-231 tumor growth in vivo. | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:719341-1 | |
| Safety | NA |